182 related articles for article (PubMed ID: 21059378)
1. Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model.
Roa WH; Azarmi S; Al-Hallak MH; Finlay WH; Magliocco AM; Löbenberg R
J Control Release; 2011 Feb; 150(1):49-55. PubMed ID: 21059378
[TBL] [Abstract][Full Text] [Related]
2. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles.
Azarmi S; Tao X; Chen H; Wang Z; Finlay WH; Löbenberg R; Roa WH
Int J Pharm; 2006 Aug; 319(1-2):155-61. PubMed ID: 16713150
[TBL] [Abstract][Full Text] [Related]
3. Distribution of effervescent inhalable nanoparticles after pulmonary delivery: an in vivo study.
Al-Hallak MH; Sarfraz MK; Azarmi S; Roa WH; Finlay WH; Rouleau C; Löbenberg R
Ther Deliv; 2012 Jun; 3(6):725-34. PubMed ID: 22838068
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin-loaded porous PLGA microparticles with surface attached TRAIL for the inhalation treatment of metastatic lung cancer.
Kim I; Byeon HJ; Kim TH; Lee ES; Oh KT; Shin BS; Lee KC; Youn YS
Biomaterials; 2013 Sep; 34(27):6444-53. PubMed ID: 23755831
[TBL] [Abstract][Full Text] [Related]
5. Secondary cytotoxicity mediated by alveolar macrophages: a contribution to the total efficacy of nanoparticles in lung cancer therapy?
Al-Hallak KM; Azarmi S; Anwar-Mohamed A; Roa WH; Löbenberg R
Eur J Pharm Biopharm; 2010 Sep; 76(1):112-9. PubMed ID: 20452423
[TBL] [Abstract][Full Text] [Related]
6. Effervescent dry powder for respiratory drug delivery.
Ely L; Roa W; Finlay WH; Löbenberg R
Eur J Pharm Biopharm; 2007 Mar; 65(3):346-53. PubMed ID: 17156987
[TBL] [Abstract][Full Text] [Related]
7. Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer.
Choi SH; Byeon HJ; Choi JS; Thao L; Kim I; Lee ES; Shin BS; Lee KC; Youn YS
J Control Release; 2015 Jan; 197():199-207. PubMed ID: 25445703
[TBL] [Abstract][Full Text] [Related]
8. Inhalable nanostructured lipid particles of 9-bromo-noscapine, a tubulin-binding cytotoxic agent: in vitro and in vivo studies.
Jyoti K; Kaur K; Pandey RS; Jain UK; Chandra R; Madan J
J Colloid Interface Sci; 2015 May; 445():219-230. PubMed ID: 25622047
[TBL] [Abstract][Full Text] [Related]
9. Formulation and in vivo evaluation of effervescent inhalable carrier particles for pulmonary delivery of nanoparticles.
Azarmi S; Lobenberg R; Roa WH; Tai S; Finlay WH
Drug Dev Ind Pharm; 2008 Sep; 34(9):943-7. PubMed ID: 18800255
[TBL] [Abstract][Full Text] [Related]
10. Preparation and properties of inhalable nanocomposite particles for treatment of lung cancer.
Tomoda K; Ohkoshi T; Hirota K; Sonavane GS; Nakajima T; Terada H; Komuro M; Kitazato K; Makino K
Colloids Surf B Biointerfaces; 2009 Jul; 71(2):177-82. PubMed ID: 19264458
[TBL] [Abstract][Full Text] [Related]
11. Folate-mediated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting drug delivery.
Zhang C; Zhao L; Dong Y; Zhang X; Lin J; Chen Z
Eur J Pharm Biopharm; 2010 Sep; 76(1):10-6. PubMed ID: 20472060
[TBL] [Abstract][Full Text] [Related]
12. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.
Wong HL; Rauth AM; Bendayan R; Wu XY
Eur J Pharm Biopharm; 2007 Mar; 65(3):300-8. PubMed ID: 17156986
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin-loaded nanoparticles consisted of cationic- and mannose-modified-albumins for dual-targeting in brain tumors.
Byeon HJ; Thao le Q; Lee S; Min SY; Lee ES; Shin BS; Choi HG; Youn YS
J Control Release; 2016 Mar; 225():301-13. PubMed ID: 26826308
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin encapsulated in sterically stabilized liposomes is superior to free drug or drug-containing conventional liposomes at suppressing growth and metastases of human lung tumor xenografts.
Sakakibara T; Chen FA; Kida H; Kunieda K; Cuenca RE; Martin FJ; Bankert RB
Cancer Res; 1996 Aug; 56(16):3743-6. PubMed ID: 8706018
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin-loaded highly porous large PLGA microparticles as a sustained- release inhalation system for the treatment of metastatic lung cancer.
Kim I; Byeon HJ; Kim TH; Lee ES; Oh KT; Shin BS; Lee KC; Youn YS
Biomaterials; 2012 Aug; 33(22):5574-83. PubMed ID: 22579235
[TBL] [Abstract][Full Text] [Related]
16. Formulation development of albumin based theragnostic nanoparticles as a potential delivery system for tumor targeting.
Kolluru LP; Rizvi SA; D'Souza M; D'Souza MJ
J Drug Target; 2013 Jan; 21(1):77-86. PubMed ID: 23036042
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy.
Kaminskas LM; McLeod VM; Ryan GM; Kelly BD; Haynes JM; Williamson M; Thienthong N; Owen DJ; Porter CJ
J Control Release; 2014 Jun; 183():18-26. PubMed ID: 24637466
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin-loaded glycyrrhetinic acid-modified alginate nanoparticles for liver tumor chemotherapy.
Zhang C; Wang W; Liu T; Wu Y; Guo H; Wang P; Tian Q; Wang Y; Yuan Z
Biomaterials; 2012 Mar; 33(7):2187-96. PubMed ID: 22169820
[TBL] [Abstract][Full Text] [Related]
19. Polymeric nanoparticles of cholesterol-modified glycol chitosan for doxorubicin delivery: preparation and in-vitro and in-vivo characterization.
Yu JM; Li YJ; Qiu LY; Jin Y
J Pharm Pharmacol; 2009 Jun; 61(6):713-9. PubMed ID: 19505361
[TBL] [Abstract][Full Text] [Related]
20. A specific peptide ligand-modified lipid nanoparticle carrier for the inhibition of tumor metastasis growth.
Wang Z; Yu Y; Dai W; Cui J; Wu H; Yuan L; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
Biomaterials; 2013 Jan; 34(3):756-64. PubMed ID: 23117217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
